Pharmaceuticals & Therapeutics

China’s top infant formula maker is rewriting the global playbook, using cutting-edge research and local insight to challenge established giants in Southeast Asia.

The Our Health Our Wellness campaign aims to close critical health disparity gaps with resources, events, and education for underserved communities.

Glenmark Pharmaceuticals challenges established brands with its new GLN-Minoxidil 5% foam, aiming to make hair regrowth treatment more accessible and convenient.

NewBeauty's 16th annual awards spotlight 395 winners, signaling a major shift towards science-backed efficacy and holistic health in the beauty market.

Longhorn Diagnostics unveils LHNVD-501, a novel antibody targeting a universal bacterial component, offering a new front against AMR and chronic inflammation.

Biotech startup Infinimmune's 'human-first' AI platform lands a major deal with Merck, aiming to revolutionize how new antibody drugs are created.

The pharma giant expands its collaboration with OpenProtein.AI, integrating advanced AI to accelerate the creation of new drugs for cancer and autoimmune diseases.

A new Phase 2 trial for an oral pill offers hope for patients with M. abscessus lung disease, a severe infection with no approved treatments.

The neurotech pioneer reports strong sales for its spinal cord injury therapy, secures key FDA approvals, and plans for major US stock market entry.

With improved financials and progress on therapies for cannabis use disorder and Down syndrome, the French biotech charts a confident course for the future.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

LIB Therapeutics' new monthly, room-temperature stable cholesterol drug shows strong long-term data, challenging rivals with a focus on patient ease-of-use.

After promising results in a key patient subgroup, the PREVAiLS study will test if pridopidine can slow the relentless progression of ALS.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.

As millions grapple with Cannabis Use Disorder, a small biotech's lead drug enters Phase 3 trials, promising the first-ever FDA-approved treatment.

PMGC Holdings touts major acquisitions and a promising biotech pipeline, but a look at its financials reveals a high-stakes bet on future growth.

NUCOT celebrates patients thriving 25+ years post-transplant, setting new global benchmarks in survival rates through advanced care and resilience.

Now the deadliest cancer for Americans under 50, advocates descend on Washington to demand urgent research funding for a growing national health crisis.

The Norwegian innovator reports strong operational progress but faces uncertainty as a crucial NOK 158 million share placement is delayed until Q2 2026.

New research on ILUMYA, LEQSELVI, and WINLEVI shows sustained efficacy and faster results, aiming to transform treatment for millions of patients.